PLos One:与心脏移植受者β阻滞剂和心率相关的尿蛋白质组学特征

2018-09-25 xiangting MedSci原创

HTx手术后尽早开始使用BB是有益的。

心脏移植(HTx)受者由于移植物去神经而出现心率高(HR),并经常开始使用β阻滞剂(BB)。这项研究评估了HTx后BB和HR是否与特定的尿蛋白质组学特征相关。

在336例HTx患者中(平均年龄56.8岁;22.3%为女性),研究人员分析了HTx后7.3年(中位数)获得的横断面数据。研究人员记录了药物使用情况、右心导管检查中测量的HR,并应用毛细管电泳结合质谱法确定了多维尿分类标志HF1和HF2(已知与左室功能障碍有关)、ACSP75(急性冠状动脉综合征)和CKD273(肾功能障碍)和48个显示亲代蛋白质的测序尿肽。

在调整后的分析中,BB使用者的HF1、HF2和CKD273(p≤0.024)高于非使用者,ACSP75也有相似的趋势(p=0.06)。HTx后1年内开始BB治疗的患者和非使用者HF1和HF2水平相似(p≥0.098),而与非使用者相比,开始BB治疗较晚与较高的HF1和HF2相关(p≤0.014)。根据HR,尿生物标志物没有差异(p≥0.27)。使用BB与尿液中胶原蛋白II和III片段的水平较高相关,而非使用者的胶原蛋白I片段水平较高。

使用BB,而不是HR,与一种尿蛋白质组学特征相关,这种尿蛋白质组学特征通常与较差的预后相关,因为不健康的状况可能导致使用BB。HTx手术后尽早开始使用BB是有益的。

原始出处:

本文系梅斯医学(MedSci)原创译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790269, encodeId=ea7f1e902690d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Feb 12 17:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718233, encodeId=c3b41e182339d, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Wed Nov 07 20:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765738, encodeId=5c121e65738d0, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 23:10:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085804, encodeId=2759208580498, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Apr 05 04:10:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754836, encodeId=c6ad1e54836dd, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sat Feb 23 18:10:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297052, encodeId=c78a129e05254, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332285, encodeId=982e1332285f6, content=<a href='/topic/show?id=33994e50466' target=_blank style='color:#2F92EE;'>#尿蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47504, encryptionId=33994e50466, topicName=尿蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790269, encodeId=ea7f1e902690d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Feb 12 17:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718233, encodeId=c3b41e182339d, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Wed Nov 07 20:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765738, encodeId=5c121e65738d0, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 23:10:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085804, encodeId=2759208580498, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Apr 05 04:10:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754836, encodeId=c6ad1e54836dd, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sat Feb 23 18:10:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297052, encodeId=c78a129e05254, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332285, encodeId=982e1332285f6, content=<a href='/topic/show?id=33994e50466' target=_blank style='color:#2F92EE;'>#尿蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47504, encryptionId=33994e50466, topicName=尿蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1790269, encodeId=ea7f1e902690d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Feb 12 17:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718233, encodeId=c3b41e182339d, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Wed Nov 07 20:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765738, encodeId=5c121e65738d0, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 23:10:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085804, encodeId=2759208580498, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Apr 05 04:10:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754836, encodeId=c6ad1e54836dd, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sat Feb 23 18:10:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297052, encodeId=c78a129e05254, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332285, encodeId=982e1332285f6, content=<a href='/topic/show?id=33994e50466' target=_blank style='color:#2F92EE;'>#尿蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47504, encryptionId=33994e50466, topicName=尿蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1790269, encodeId=ea7f1e902690d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Feb 12 17:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718233, encodeId=c3b41e182339d, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Wed Nov 07 20:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765738, encodeId=5c121e65738d0, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 23:10:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085804, encodeId=2759208580498, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Apr 05 04:10:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754836, encodeId=c6ad1e54836dd, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sat Feb 23 18:10:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297052, encodeId=c78a129e05254, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332285, encodeId=982e1332285f6, content=<a href='/topic/show?id=33994e50466' target=_blank style='color:#2F92EE;'>#尿蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47504, encryptionId=33994e50466, topicName=尿蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2019-04-05 zhyy88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1790269, encodeId=ea7f1e902690d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Feb 12 17:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718233, encodeId=c3b41e182339d, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Wed Nov 07 20:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765738, encodeId=5c121e65738d0, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 23:10:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085804, encodeId=2759208580498, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Apr 05 04:10:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754836, encodeId=c6ad1e54836dd, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sat Feb 23 18:10:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297052, encodeId=c78a129e05254, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332285, encodeId=982e1332285f6, content=<a href='/topic/show?id=33994e50466' target=_blank style='color:#2F92EE;'>#尿蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47504, encryptionId=33994e50466, topicName=尿蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1790269, encodeId=ea7f1e902690d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Feb 12 17:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718233, encodeId=c3b41e182339d, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Wed Nov 07 20:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765738, encodeId=5c121e65738d0, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 23:10:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085804, encodeId=2759208580498, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Apr 05 04:10:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754836, encodeId=c6ad1e54836dd, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sat Feb 23 18:10:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297052, encodeId=c78a129e05254, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332285, encodeId=982e1332285f6, content=<a href='/topic/show?id=33994e50466' target=_blank style='color:#2F92EE;'>#尿蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47504, encryptionId=33994e50466, topicName=尿蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1790269, encodeId=ea7f1e902690d, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Feb 12 17:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718233, encodeId=c3b41e182339d, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Wed Nov 07 20:10:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765738, encodeId=5c121e65738d0, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 26 23:10:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085804, encodeId=2759208580498, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Apr 05 04:10:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754836, encodeId=c6ad1e54836dd, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sat Feb 23 18:10:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297052, encodeId=c78a129e05254, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332285, encodeId=982e1332285f6, content=<a href='/topic/show?id=33994e50466' target=_blank style='color:#2F92EE;'>#尿蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47504, encryptionId=33994e50466, topicName=尿蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Thu Sep 27 07:10:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]

相关资讯

Eur J Heart Fail:心脏移植者晚期移植物衰竭的发生率、危险因素及临床结局!

由此可见,心脏移植后晚期移植物衰竭较为常见,因为它与不良结局有关。排斥反应和移植心脏血管病是最常见的原因。

JACC:心脏移植后初始免疫抑制治疗:西罗莫司vs钙调神经磷酸酶抑制剂

2018年2月,发表于《J Am Coll Cardiol》上的一项研究,考察了心脏移植(HT)受者长期使用西罗莫司(SRL)进行初始免疫抑制治疗的效果。

Sci Rep:心脏康复期间心脏移植和左心室辅助装置植入患者之间生化标志物的差异

在康复期间,应注意HTx患者早期出现的血脂异常和高血糖,这需要适当的蛋白质膳食支持。LVAD患者中很低的IGF-1可能导致患者的康复预后差。

Heart:作为移植过渡的左心室辅助装置患者的生存率及治疗预后

在重度心衰且预后极差的患者人群中,使用植入式LVAD支持使得四分之一的患者在3年内接受了心脏移植。

JACC:西罗莫司缓解心脏移植后免疫反应更佳

既往有报道称西罗莫司(SRL)在缓解心脏移植后的移植物血管病(CAV)方面的效果要优于钙调神经磷酸酶抑制剂(CNI),然而缺乏远期的疗效报道。本研究旨在评估用SRL代替CNI作为维持治疗心脏移植后的CAV远期的有效性和安全性。本研究纳入了402例心脏移植后的患者,这些患者有的仅接受CNI治疗(n = 134),有的用SRL代替了CNI作为一级免疫抑制预防治疗(n = 268),CAV通过冠脉血管内

JACC:儿童心脏支持技术为心脏移植提供了有力保障

小儿心室辅助装置(VAD)在近二十年来发展迅速。本研究的目的旨在描述VAD的发展及其支持下的儿童心脏移植(HTx)。本研究的数据来自小儿心脏移植研究数据库,比较了VAD支持下的小儿心脏移植和由体外膜肺氧合(ECMO)转至VAD支持下的儿童心脏移植。最终共纳入了5145例儿童心脏移植患者,其中995例(19.3%)是在VAD支持下进行的。与由ECMO转至VAD的患者(164例)相比,直接首次装配VA